ephrin-a5 has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doi, N; Esaki, M; Hiraoka, N; Ino, Y; Ishimoto, U; Iwasaki, T; Kishi, Y; Naito, C; Nakajima, K; Nara, S; Shimada, K; Shimasaki, M | 1 |
| Chen, HT; Lu, XX; Shen, BY; Sun, B; Wang, JW; Wang, ZT; Xie, J; Xing, S | 1 |
2 other study(ies) available for ephrin-a5 and Pancreatic Neoplasms
| Article | Year |
|---|---|
Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5.
Topics: Antineoplastic Agents; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Proliferation; Collagen; Ephrin-A5; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Primary Cell Culture; Retrospective Studies; Signal Transduction; Tumor Cells, Cultured; Tumor Microenvironment | 2022 |
PIWIL1 interacting RNA piR-017061 inhibits pancreatic cancer growth via regulating EFNA5.
Topics: Argonaute Proteins; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Ephrin-A5; Epistasis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; RNA, Small Interfering | 2021 |